Stay updated with breaking news from கிறிஸ்டினா செங். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Alcon Inc. Investors: Alcon Reinforces Strength of Industry-Leading Ophthalmology Portfolio with Largest Surgical Device Scientific Presence at ASCRS 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Alcon Inc. Swiss: Alcon Announces Executive Committee Changes finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Alcon Inc. Investors: Alcon Announces Executive Committee Changes finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Alcon Inc. Swiss: Alcon Reports First Quarter 2021 Results Strong commercial execution drives the global launch of new product innovations Substantially completes separation process Full year guidance: sales of $7.8 to $8.0 billion and core diluted EPS of $1.85 to $1.95 Regulatory News: Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2021. For the first quarter of 2021, worldwide sales were $1.9 billion, an increase of 5% on a reported basis and 2% on a constant currency basis (2), as compared to the same quarter of the previous year. First quarter 2021 diluted earnings per share were $0.17 and core diluted earnings per share were $0.49. ....
Alcon Inc. Swiss: Alcon to Acquire U.S. Commercialization Rights to Ophthalmic Eye Drop Simbrinza Builds on company s ophthalmic pharmaceutical manufacturing expertise Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza The acquisition of Simbrinza combined with the company s existing over-the-counter (OTC) eye drops will give Alcon a strong ophthalmic eye drop portfolio and the opportunity to capitalize on both the large glaucoma market and the fast-growing dry eye preservative free and eye allergy markets. The company s strong U.S. ophthalmology expertise and existing relationships with healthcare professionals (HCP) will help drive HCP and patient adoption. ....